Recursion Pharmaceuticals Inc (RXRX) Q3 2026 Earnings Call Highlights: Durable FAP Data

Recursion Pharmaceuticals (RXRX) discussed Q3 2026 earnings, highlighting durable FAP data for REC-481, showing 92% of patients maintained polyp burden reduction after 12 weeks off treatment. CEO Najat emphasized AI-driven differentiation and data-driven capital allocation, with $535M in cash inflows from partnerships. REC-1245 showed early promise in endometrial cancer. The company guided to lower operating expenses in 2027 and has runway into 2029.

Original reporting
Published Nov 11, 2026, 1:07 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 11, 2026, 1:28 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Recursion Pharmaceuticals Inc (RXRX) Q3 2026 Earnings Call Highlights: Durable FAP Data — source image
Decision brief

The 30-second read

$RXRXNeutralLow
01

Why it matters

The call provided the first public durability metrics for REC‑481 and early efficacy signals for REC‑1245, offering a modest catalyst for the stock.

02

Market read

First‑time durability data may slightly improve sentiment for Recursion, but overall impact remains limited without later‑stage trial confirmation.

03

What to watch

Capital runway to 2029 reduces near‑term financing risk, but high cash burn could pressure valuation if milestones slip.

Relevance 4/10Novelty 4/10Timing: post‑earnings call

Background

Recursion's Q3 2026 earnings call covered pipeline updates, AI platform capabilities, and financial runway.

Company-level read

Ticker impact

$RXRXNeutralMedium confidence
Context

Recursion disclosed durability data showing 92% of patients maintain polyp reduction after 12 weeks off treatment and discussed early-phase trial results for REC-481 and REC-1245.

Expected impact

likely slight upward pressure as investors weigh durability data against early-stage risk

Evidence & confidence

First disclosure of durability metrics provides new, but limited, catalyst; impact depends on later Phase 3 outcomes.

Market effects

Highlights AI‑driven drug discovery progress, may boost interest in biotech AI peers.

US biotech sector may see modest lift; European markets less affected.

Limited to investors tracking early‑stage biotech pipelines.

Counterpoint

Durability data is early and based on small cohorts; investors may remain skeptical until Phase 3 confirms efficacy.

Key entities

  • Recursion Pharmaceuticals Inc

    US‑listed biotech developing AI‑driven therapies.

  • Najat V. (CEO)

    Chief Executive Officer of Recursion.

  • Vicki (CMO)

    Chief Medical Officer of Recursion.

Related articles

$RXRXMed

Recursion Aligns With FDA On Phase 3 Trial Design For FAP Drug REC-4881; Stock Up

Recursion Pharmaceuticals (RXRX) aligned with the FDA on the Phase 3 trial design for REC-4881, an oral MEK1/2 inhibitor for familial adenomatous polyposis (FAP). The trial, expected to start in late 2027, will assess composite event-free survival as the primary endpoint. REC-4881 has shown a 47% median reduction in total polyp burden in Phase 1b/2 trials. RXRX shares were up 4.41% in premarket trading.

$RXRXMedAI 8/10

Recursion (RXRX) Q3 2026 Earnings Call Transcript

Recursion (RXRX) reported Q3 2026 earnings, highlighting clinical data for REC-4881 and REC-1245. REC-4881 showed significant reductions in polyp burden and safety. REC-1245 demonstrated early activity in solid tumors. The company secured $535M in partner cash inflows and extended cash runway to 2029. Operating expenses for 2026 were lowered to $375M, with 2027 expected under $360M. Sanofi and Roche collaborations advanced, with milestones and royalties. Fred Hassan was appointed board chair.

$RXRXMedAI 8/10

What Recursion Pharmaceuticals (RXRX) Said on Its Q3 Earnings Call

Recursion Pharmaceuticals (RXRX) reported Q3 updates, including 55% and 50% median reductions in upper and lower GI polyp burdens, respectively. REC-1245 showed partial responses in advanced solid tumors. Sanofi exercised an option, triggering a $10M payment. RXRX raised $200M in financing, extending cash runway into 2029. The company expects to start a registrational study in 2H 2027.

$RXRXHighAI 8/10

Recursion's Q3 Earnings Beat Estimates on Sanofi Milestone Revenues

Recursion Pharmaceuticals reported a narrower-than-expected Q3 2026 loss of 22 cents per share, with revenues of $18.55 million, up 258.5% YoY, driven by a $10 million Sanofi milestone payment. Operating expenses declined, and the company advanced its pipeline, including REC-4881 and REC-1245. RXRX shares are down 6.4% YTD.